This Assessment reviews the available evidence to determine whether, compared with the established alternatives, nonmyeloablative allogeneic stem-cell transplantation improves the net health outcome of three patient groups:

- those with chronic myeloid leukemia, acute lymphocytic or myeloid leukemia, Hodgkin's disease, or non-Hodgkin's lymphoma who are ineligible for conventional high-dose chemotherapy (HDC) or allogeneic transplantation of stem cells (alloSCT) because of advanced age, poor organ function, or comorbid conditions;

- those with multiple myeloma or other hematologic malignancies for which evidence on the outcomes of conventional HDC/alloSCT is insufficient to permit conclusions; and

- those with renal cancer or other tumors of solid tissues or organs.